Frontlight ResearchEarly access
CompletedPhase 4
Effect of Dupilumab on nasal epithelial barrier function in patients with Chronic Rhinosinusitis with nasal polyps (CRSwNP) – an exploratory pilot study
Key facts
- Who runs it
- Medical University Of Vienna
- Where
- Austria1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 80 people enrolled
- Started
- 15 May 2024
- Ended
- 22 May 2026
- Type of study
- Interventional
- Record updated
- 6 May 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- 18-99 years of age
- Willingness to participate in the study
- Suffer from chronic rhinosinusitis defined as in EPOS 2020 criteria, see main text
- Group 1 (n=20, CRSsNP): Absence of nasal polyps
- Group 2 (N=60, CRSwNP): Presence of nasal polyps as confirmed by endoscopy or CT and planned therapy with dupilumab
- Presence or absence of non-steroidal anti-inflammatory drug (NSAID)-Exacerbated Respiratory Disease (N-ERD)
- Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 6 months has passed
Who cannot take part
- Patients with a history of exacerbation of chronic rhinosinusitis 4 weeks prior to the screening visit
- Intake of a burst of systemic corticosteroids for the treatment of CRS 4 weeks prior to the screening visit
- A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- Pregnancy (as determined by ß-HCG test) or breast feeding
- Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity
- Patients with cystic fibrosis or primary ciliary dyskinesia
- Patients with permanent immunosuppression
- Patients with clinically meaningful comorbidity as determined by the evaluating committee
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
• To characterize differences in barrier function of the nasal epithelium in patients suffering from CRSsNP or CRSwNP (in absence of therapy with monoclonal antibodies) and disease controls in response to challenges with various harmful substances in cultured primary nasal- and polyp-derived epithelial cells. • Effect of dupilumab treatment on barrier function of the nasal epithelium in patients suffering from CRSwNP.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 6 May 2024